An important contract was signed Monday between Debiopharm and Merck. The Vaud group grants the German giant an exclusive worldwide license for the development and marketing of Xevinapant, a phase 3 drug against head and neck cancer. Debiopharm will receive an initial payment of 188 million euros (207 million francs), several installments up to 710 million euros depending on the stages of development and fees on any sales.
“This drug has the potential to become a blockbuster (Editor’s note: a product with annual sales exceeding one billion dollars), ”says Thierry Mauvernay. The boss of Debiopharm indicates that this product reduces the risk of death by 51% compared to the standard treatment of patients who benefited from it during a phase 2 study (out of a hundred people). “With three years of hindsight, we can say that Xevinapant does not only cure cancer, it allows it to be cured. These are exceptional results. ”